Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(04): 406-408
DOI: 10.4103/wjnm.WJNM_112_18
Case Report

177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

Majid Assadi
The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran
,
Hojjat Ahmadzadehfar
1   Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with 177Lu-DOTATATE and 177Lu-PSMA, presumably as a first report in this regard.

Keywords

177Lu - DOTATATE - prostate-specific membrane antigen - radioiodine-refractory differentiated thyroid cancer

Financial support and sponsorship

Nil.




Publication History

Received: 11 December 2018

Accepted: 21 December 2018

Article published online:
22 April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nucl Med 2016;46:215-24.
  • 2 Roll W, Riemann B, Schäfers M, Stegger L, Vrachimis A 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: A Single center experience. Clin Nucl Med 2018;43:e346-51.
  • 3 Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: Opening a new horizon in management of thyroid cancer? Clin Nucl Med 2016;41:e263-5.
  • 4 Sager S, Vatankulu B, Uslu L, Sönmezoglu K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. J Nucl Med Technol 2016;44:199-200.
  • 5 Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using(90) Yttrium and (177)Lutetium labeled somatostatin analogs: Toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 2013;4:39-52.
  • 6 Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: A new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 2014;24:715-26.